This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmiemann, V. Articles by Grote, H. J. Search for Related Content PubMed PubMed Citation Articles by Schmiemann, V. Articles by Grote, H. J.

Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study

Authors' Affiliations: ¹ Institut fuer Cytopathologie and ² Institut fuer Pathologie, Heinrich-Heine-Universitaet; ³ Klinik fuer Pulmologie, Florence-Nightingale-Krankenhaus, Duesseldorf, Germany; and ⁴ Institut fuer Pathologie, Ev. Krankenhaus Bethesda, Duisburg, Germany

Requests for reprints: Hans Juergen Grote, Institut fuer Cytopathologie, Heinrich-Heine-Universitaet, Moorenstrasse 5, D-40225 Duesseldorf, Germany. Phone: 49-211-8118837; Fax: 49-211-8118402; E-mail: grote{at}med.uni-duesseldorf.de.

Purpose: Recent studies have detected aberrant promoter methylation of adenomatous polyposis coli promoter 1 A (APC), cyclin-dependent kinase inhibitor-2A (p16^INK4a), retinoic acid receptor ß2, and RAS association domain family protein 1 (RASSF1A) in bronchial aspirates and suggested their use as biomarkers for lung cancer diagnostics. The purpose of this study was to validate these candidate marker genes in a retrospective cohort study.

Experimental Design: Bronchial aspirates collected from a cohort comprising 247 patients with suspected lung cancer were investigated retrospectively regarding aberrant promoter methylation using a quantitative methylation-specific real-time PCR (QMSP).

Results: Eighty-nine patients were diagnosed with primary lung cancer, 102 had benign lung disease, and 56 showed miscellaneous other conditions. A panel consisting of APC, p16^INK4a, and RASSF1A emerged as useful combination. This panel detected aberrant methylation in bronchial aspirates of 22 of 35 (63%) and 21 of 44 (44%) centrally and peripherally located primary lung cancers, respectively. Bronchial aspirates also showed aberrant methylation in 5 of 7 (71%) patients with a recurrent lung cancer and in 8 of 30 (27%) cases without tumor recurrence. In contrast, only 1 of 102 patients with benign lung disease displayed a (false) positive test result. Rarely, aberrant methylation was found in patients with other malignancies (3 of 16). The QMSP assay correctly confirmed lung cancer in 8 of 12 (67%) cases with an ambiguous cytology. Moreover, it disclosed 9 of 26 (35%) of peripheral tumors lacking simultaneous cytologic or histologic diagnosis of malignancy.

Conclusions: Our findings suggest that the QMSP assay could be applied as a reflex test in cases of suspected lung cancer that defy a definite diagnosis by conventional methods. Thus, the assay could be a useful diagnostic adjunct especially regarding peripheral tumors.

This article has been cited by other articles:

				W. K. DE JONG, G. F. VERPOOTEN, H. KRAMER, J. LOUWAGIE, and H. J.M. GROEN Promoter Methylation Primarily Occurs in Tumor Cells of Patients with Non-small Cell Lung Cancer Anticancer Res, January 1, 2009; 29(1): 363 - 369. [Abstract] [Full Text] [PDF]

				H.-J. Haussmann Smoking and Lung Cancer: Future Research Directions International Journal of Toxicology, July 1, 2007; 26(4): 353 - 364. [Abstract] [Full Text] [PDF]